![Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials | Neurology Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials | Neurology](https://n.neurology.org/content/neurology/92/14/e1610/T3/graphic-4.medium.gif)
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials | Neurology
![Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial - eBioMedicine Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial - eBioMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/60edcec6-04c6-49d6-94a3-f0f5a1f135d5/gr1.jpg)
Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial - eBioMedicine
![Frontiers | Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates Frontiers | Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates](https://www.frontiersin.org/files/Articles/455919/fneur-10-00835-HTML/image_m/fneur-10-00835-g001.jpg)
Frontiers | Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates
![Frontiers | ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Frontiers | ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?](https://www.frontiersin.org/files/Articles/221704/fnagi-09-00068-HTML/image_m/fnagi-09-00068-t001.jpg)
Frontiers | ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
![Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? - The Lancet Neurology Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2105742108/2081270905/gr1.jpg)
Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? - The Lancet Neurology
![Frontiers | Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement Frontiers | Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement](https://www.frontiersin.org/files/MyHome%20Article%20Library/281026/281026_Thumb_400.jpg)